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A commentary on
Hypnotic Medications and Suicide: Risk, Mechanisms, Mitigation, and the FDA
by McCall WV, Benca RM, Rosenquist PB, Riley MA, McCloud L, Newman JC, et al. Am J Psychiatry 
(2016). doi:10.1176/appi.ajp.2016.16030336
McCall and colleagues (1) recently published a review entitled “Hypnotic Medications and Suicide: 
Risk, Mechanisms, Mitigation, and the FDA” in the September 2016 issue of the American Journal 
of Psychiatry. They noted that although epidemiological studies have demonstrated that hypnotic 
sedatives are associated with an increased risk for suicide, none of these studies adequately have 
controlled for depression and/or other psychiatric disorders. However, McCall et al. conclude that 
their review findings indicate that hypnotic sedative medications are associated with suicidal idea-
tion and that future studies should assess whether increases in suicidality result from CNS impair-
ments from a given hypnotic medication or whether such medication decreases suicidality because 
of improvements in insomnia (1).
We believe there is a difference between the following two clinical situations, e.g., when suicide 
is induced by the recommended use of certain hypnotic medication for insomnia versus when the 
hypnotic sedative medication is used simply as a vehicle to commit suicide. Clearly, excessive use of 
any substance can potentially be harmful and even fatal. Pure water, for example, if taken in excessive 
quantity, may cause serious complications, including death (2). The first case of self-induced water 
intoxication was reported in 1938 by Barahal (3). Epidemiologically, several lines of accumulating 
evidence have indicated that polydipsia was found in 6–17% of chronic psychiatric patients. A total 
of 25–50% of psychiatric patients with polydipsia have been reported to have symptoms of water 
intoxication (4). Under such circumstances, therefore, the relationship between deaths and water 
intoxication is of causality rather than association. Yet, there are no such warnings as, “Water use may 
cause deaths” or “drinking water is associated with deaths” on any water bottles. Overwhelmed Web 
information is already a problem for patients to look for evidence about the drug they are taking, 
which may adversely impact their expectations about their improvement.
We question the true benefit of mingling every possible association conceivable of any drug into 
its lengthy package insert. We know that physicians typically do not read the entire prescribing 
information provided in the FDA-approved package insert (FDA-PI) (5). Nevertheless, such warn-
ings are generalized and copied into the PIs of other drugs of the same class. Such narratives may 
potentially be used as evidence in court in medico-legal processes, even when such association may 
not even be significant or even true. For example, in the FDA-approved PI of buprenorphine, there 
is a statement: “Because of the partial agonist properties of buprenorphine, sublingual tablets may 
precipitate opioid withdrawal signs and symptoms …” (6). The term “opioid withdrawal” is actually 
mentioned over 20 times in the buprenorphine PI. Yet, both the preclinical and clinical data reviewed 
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by van Niel et  al. (7) clearly demonstrate that buprenorphine 
can be combined with a full MOP agonist, without precipitating 
opioid withdrawal.
Finally, we are concerned about placing every possible asso-
ciation into the FDA-PI can even do potential harm to certain 
patients (e.g., those who choose to read the PI) via the triggering 
of a nocebo effect, which occurs when the expectation of a nega-
tive outcome precipitates the corresponding symptom or leads 
to its exacerbation. Nocebo responses demonstrate the powerful 
interaction between the therapeutic context and the patient’s 
mind–brain interaction. Studies have shown that difference in 
disclosure information about adverse events results in different 
clinical responses (8). Rigorous previous research has suggested 
that providing patients with a detailed enumeration of every 
possible adverse event can actually increase such side effects (9). 
The dilemma is when the harmfulness of the nocebo effect may 
outweigh the good in proper disclosure of medical information 
to the patient, and where the duty to inform may therefore be 
suspended (10).
To minimize the harmful nocebo effect which might be 
brought about from the disclosure of all possible associations of 
hypnotics, such as that with suicide, we wonder if it might be 
a good and pragmatic idea to disclose those strong associations 
or clear causality, but withhold those trivial or weak associations 
which might potentially turn out to be more harmful in triggering 
a nocebo effect when disclosed in the FDA-PI.
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